ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

N4P N4 Pharma Plc

0.825
0.00 (0.00%)
Last Updated: 10:31:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
N4 Pharma Plc LSE:N4P London Ordinary Share GB00BYW8QM32 ORD 0.4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.825 0.80 0.85 0.85 0.80 0.80 2,358,877 10:31:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Drug & Proprietary Stores 0 -1.03M -0.0057 -1.44 1.48M
N4 Pharma Plc is listed in the Drug & Proprietary Stores sector of the London Stock Exchange with ticker N4P. The last closing price for N4 Pharma was 0.83p. Over the last year, N4 Pharma shares have traded in a share price range of 0.625p to 2.20p.

N4 Pharma currently has 181,080,349 shares in issue. The market capitalisation of N4 Pharma is £1.48 million. N4 Pharma has a price to earnings ratio (PE ratio) of -1.44.

N4 Pharma Share Discussion Threads

Showing 2326 to 2350 of 8600 messages
Chat Pages: Latest  104  103  102  101  100  99  98  97  96  95  94  93  Older
DateSubjectAuthorDiscuss
16/2/2018
20:11
And don`t forget that we have N4`s final results next month too.
I am looking forward to that as I think it will make for a pleasant read.

hughwilson
16/2/2018
20:00
Parob,
We have the might of the Japanese pharma industry attending this conference and they will be listening to Nigel's speech on Nuvec and sitting down at the table with him to discuss collaborations or deals. There can be no way that the market could have digested the significance of that. Any hint of a deal will see N4's shares surge.

hughwilson
16/2/2018
19:47
Perfect place to do business:



Cell and gene therapy has become a priority area for the Japanese government. Japan is focused on the need to collaborate with the national and international industry to pursue the commercialisation of new scientific discoveries. This, in parallel with the implementation of the New Japanese Regulatory Frameworks for Clinical Research and Marketing Authorisation of Gene Therapy and Cellular Therapy Products speeding up getting products to the market and facilitating the understanding of regulations by foreign operators promoting translational cooperation, makes Japan an attractive market in this field. Licensing, partnering, outsourcing, development and commercialisation opportunities abound, but collaboration is absolutely critical to the success of each one.

parob
16/2/2018
18:22
Look out for press coverage this weekend.
Next week should see a strong performance for N4.

hughwilson
16/2/2018
16:56
jimbobaroony, i suspect that since you said you had sold half your holding at 25, your remaining shares possibly amount to a relatively small position here, so you can afford to be fairly laid back. The actual bid price at the end was over 33p not 32p as quoted
PS have a good holiday.

neftanikoff
16/2/2018
16:43
Good luck next week. I'm on holiday so won't be posting. Some of you will miss me I know. I've left my existing holding as is. No stop loss or sell at any price. Fingers crossed I get back and this is at record high.
jimbobaroony
16/2/2018
16:35
Great week guys. Real momentum building here now.Looking forward to next week already! Could the Nuvec point of different news be released whilst they're in Japan!?
parob
16/2/2018
16:27
100k followed by a 50k buy.
MM`s increasing the spread to disguise the strength of the finish.

hughwilson
16/2/2018
16:25
guys welldone , , hope we have an news at the back end of next week rather than early part ,see you next week
falia
16/2/2018
16:24
The 100,000 share trade listed as a sell is in fact a buy from earlier.
If institutions have not started buying already, they soon will do.

hughwilson
16/2/2018
16:23
100K delayed buy now showing from 15.20
parob
16/2/2018
16:22
another awesome week, now the big week coming up
falia
16/2/2018
16:22
another awesome week, now the big week coming up
falia
16/2/2018
16:20
£5=£10 long term target at the least
falia
16/2/2018
16:19
10 mins to load up
falia
16/2/2018
16:14
I expect that Myles will put a valuation of at least 3 figures per share and that is only including the additional value of Nuvec.
That valuation could be outdated as early as next week if news from Japan starts rolling in.

hughwilson
16/2/2018
16:09
Yup good choice longterm, still plenty to go for!!
escapetohome
16/2/2018
16:08
35p coming up
falia
16/2/2018
15:58
Just bought in folks, great looking business model, and opportunity. Looking forward to hearing how the company get on next week.Thanks again parob for providing that information yesterday.Gla.
l0ngterm
16/2/2018
15:30
Big old finish looks on the cards IMO. Can't wait until next week!
qs99
16/2/2018
15:27
Yep, 33p being paid . Massive finish in prospect.. wouldn’t want to be out of these going into the eeekend and into next week...
jakleeds
16/2/2018
15:27
III NNN EEE XXX OOO RRR AAA BBB LLL EEE x 3

Why?

Because £3 is my target.

escapetohome
16/2/2018
15:26
Will we see a strong finish today?
Looking that way and that will set us up for some weekend press prior to Japan news next week.

hughwilson
16/2/2018
15:25
here comes the boom finish
falia
16/2/2018
14:59
In addition, we are still waiting for updates from both Beaufort and Myles McNulty with regard values. I would expect the valuation from Myles to be much higher as it takes account of near-term future prospects.
Myles would have spoken to Nigel prior to his trip to Japan so may have an insight into where this is going. It would not surprise me to see a valuation of well over £1 per share for the near term.

hughwilson
Chat Pages: Latest  104  103  102  101  100  99  98  97  96  95  94  93  Older

Your Recent History

Delayed Upgrade Clock